

137Caesium and Iridium sources, among others, are used in low dose rate (LDR) brachytherapy. Once the patient is in a shielded chamber, a 'applicator' is put in the cavity or inside the tumour, and the source is supplied into the applicator. They will be kept in isolation until the source is eliminated (usually 12-24 hours). This procedure frequently necessitates hospitalisation.
High dosage rate (HDR) brachytherapy, which can be given with tiny sources of 60Cobalt or 192Iridium, allowing for a dose rate of more than 12 Grays per hour and short treatment intervals. As a result, HDR can be used as an outpatient treatment option. Brachytherapy is an important part of gynaecological cancer radiation treatment.
Read More:
Click here for Brachytherapy Market Report:
https://www.coherentmarketinsights.com/market-insight/brachytherapy-market-1175





